marc_cermak

REGN trend reversal and 30% upside

Long
NASDAQ:REGN   Regeneron Pharmaceuticals, Inc.
Recently, REGN has been in a downtrend. As supported by the technical indicators, there seems to be a potential trend reversal with a potential upside of 30% as evidenced by the oversold RSI level of <30 and a potential bullish divergence. A LONG initiated at or near $460 PS supported by near fib retracement level indicates 30% upside with the upside target of $600 and downside bearish target of $398 over the next quarter.

The technicals are also supported fundamentally by strong revenue growth of 30% Y/Y and a P/E of ~15 which is abnormally low for the stock. With the strong projected growth and multiple upcoming catalysts for the stock, it poses a unique opportunity for both mid-term and long-term investors. Furthermore, analyst consensus converges to mid $700.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.